Clinical Trial Update: Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer [Phase 3]

View source ↗

Summary

This is a Phase 3 trial assessing the addition of durvalumab to standard chemotherapy for stage II-III breast cancer; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 3 | Status: RECRUITING